Haemonetics (HAE) vs Pulse Biosciences (PLSE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pulse Biosciences (PLSE) has outperformed Haemonetics (HAE) over the past year, gaining 147.1% versus a gain of 106.5%. Over five years, PLSE leads with a +126.7% price change compared with +45.5% for HAE. Haemonetics is the larger company by market cap ($5.42 billion vs $3.55 billion), about 1.5 times the size.
Haemonetics converts more of its revenue into profit, with a net margin of 7.3% versus -20794.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | PLSE |
|---|---|---|
| Share price | $119.06 | $49.80 |
| Market cap | $5.42B | $3.55B |
| 1-day change | +17.05% | +1.44% |
| YTD return | +26.90% | +257.54% |
| 1-year return | +106.48% | +147.06% |
| 5-year return | +45.49% | +126.74% |
| P/E ratio (TTM) | 57.51 | — |
| Forward P/E | 20.61 | — |
| EPS (TTM) | $2.07 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | $350.00K |
| Revenue growth (YoY) | -1.97% | — |
| Net income (latest FY) | $97.31M | $-72.78M |
| Gross margin | 59.04% | -54.00% |
| Operating margin | 11.75% | -21982.57% |
| Net margin | 7.29% | -20794.57% |
| 52-week high | $120.72 | $58.90 |
| 52-week low | $48.17 | $12.56 |
| Distance from 52-week high | -1.38% | -15.46% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -6.35% | +13.47% |
| Average volume | 678.94K | 506.50K |
| Shares outstanding | 45.50M | 71.32M |
| Employees | 3,009 | 116 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLSE has outperformed HAE by 40.6 percentage points over the past year.
- Haemonetics is more profitable, keeping 7.3 cents of every revenue dollar as net income versus -20794.6 cents for Pulse Biosciences.
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About Pulse Biosciences
PLSE stock →Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
Health Care · Medical/Dental Instruments · 116 employees
HAE vs PLSE FAQ
Which is bigger, Haemonetics or Pulse Biosciences?
Haemonetics (HAE) is larger, with a market capitalization of $5.42B compared with $3.55B for Pulse Biosciences (PLSE).
Which stock has performed better over the past year, HAE or PLSE?
PLSE returned +147.06% over the past 12 months, compared with +106.48% for HAE (price return, excluding dividends). Past performance does not predict future results.
Are Haemonetics and Pulse Biosciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.